JP2014519830A5 - - Google Patents

Download PDF

Info

Publication number
JP2014519830A5
JP2014519830A5 JP2014516311A JP2014516311A JP2014519830A5 JP 2014519830 A5 JP2014519830 A5 JP 2014519830A5 JP 2014516311 A JP2014516311 A JP 2014516311A JP 2014516311 A JP2014516311 A JP 2014516311A JP 2014519830 A5 JP2014519830 A5 JP 2014519830A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
domain
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014516311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014519830A (ja
JP6246711B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/061734 external-priority patent/WO2012175508A1/en
Publication of JP2014519830A publication Critical patent/JP2014519830A/ja
Publication of JP2014519830A5 publication Critical patent/JP2014519830A5/ja
Application granted granted Critical
Publication of JP6246711B2 publication Critical patent/JP6246711B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014516311A 2011-06-22 2012-06-19 複合体を含むｍｈｃクラスｉを用いてウイルス特異的細胞傷害性ｔ細胞を循環させることによる標的細胞の除去 Expired - Fee Related JP6246711B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11171027.3 2011-06-22
EP11171027 2011-06-22
PCT/EP2012/061734 WO2012175508A1 (en) 2011-06-22 2012-06-19 Removal of target cells by circulating virus-specific cytotoxic t-cells using mhc class i comprising complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017155048A Division JP6542303B2 (ja) 2011-06-22 2017-08-10 複合体を含むｍｈｃクラスｉを用いてウイルス特異的細胞傷害性ｔ細胞を循環させることによる標的細胞の除去

Publications (3)

Publication Number Publication Date
JP2014519830A JP2014519830A (ja) 2014-08-21
JP2014519830A5 true JP2014519830A5 (enExample) 2017-01-12
JP6246711B2 JP6246711B2 (ja) 2017-12-13

Family

ID=46319142

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014516311A Expired - Fee Related JP6246711B2 (ja) 2011-06-22 2012-06-19 複合体を含むｍｈｃクラスｉを用いてウイルス特異的細胞傷害性ｔ細胞を循環させることによる標的細胞の除去
JP2017155048A Expired - Fee Related JP6542303B2 (ja) 2011-06-22 2017-08-10 複合体を含むｍｈｃクラスｉを用いてウイルス特異的細胞傷害性ｔ細胞を循環させることによる標的細胞の除去

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017155048A Expired - Fee Related JP6542303B2 (ja) 2011-06-22 2017-08-10 複合体を含むｍｈｃクラスｉを用いてウイルス特異的細胞傷害性ｔ細胞を循環させることによる標的細胞の除去

Country Status (24)

Country Link
US (4) US20130011394A1 (enExample)
EP (1) EP2723773B1 (enExample)
JP (2) JP6246711B2 (enExample)
KR (1) KR102038155B1 (enExample)
CN (2) CN103649125A (enExample)
AR (1) AR086982A1 (enExample)
AU (1) AU2012274127B2 (enExample)
BR (1) BR112013029746B1 (enExample)
CA (1) CA2835772C (enExample)
CL (1) CL2013003634A1 (enExample)
CO (1) CO6801646A2 (enExample)
CR (1) CR20130609A (enExample)
EA (1) EA201400046A1 (enExample)
EC (1) ECSP13013098A (enExample)
ES (1) ES2667864T3 (enExample)
IL (1) IL229486B (enExample)
MA (1) MA35604B1 (enExample)
MX (1) MX354663B (enExample)
PE (1) PE20141212A1 (enExample)
PH (1) PH12013502499A1 (enExample)
PL (1) PL2723773T3 (enExample)
SG (1) SG195077A1 (enExample)
TW (1) TWI563087B (enExample)
WO (1) WO2012175508A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015011111A2 (pt) * 2012-11-30 2017-11-14 Roche Glycart Ag proteína multifuncional e formulação farmacêutica
JP2016500255A (ja) 2012-12-11 2016-01-12 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ハイスループットなレセプター：リガンド同定の方法
SG11201504414UA (en) * 2012-12-21 2015-07-30 Hoffmann La Roche Disulfide-linked multivalent mhc class i comprising multi-function proteins
CN105377297B (zh) * 2013-05-28 2019-09-17 Dcb-美国有限责任公司 用于蛋白质药物失活的抗体锁扣
SG10201710737VA (en) * 2013-06-24 2018-01-30 Neximmune Compositions and methods for immunotherapy
AU2014373593B2 (en) * 2013-12-23 2020-07-16 Zymeworks Bc Inc. Antibodies comprising C-terminal light chain polypeptide extensions and conjugates and methods of use thereof
CN112877291A (zh) * 2014-04-10 2021-06-01 西雅图儿童医院 (Dba西雅图儿童研究所) 基因修饰的t细胞产品、其制备方法和用途
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
WO2016141284A1 (en) * 2015-03-04 2016-09-09 The Johns Hopkins University Compositions and methods for enhancing an immune response
HK1256087A1 (zh) 2015-08-07 2019-09-13 Seattle Children's Hospital, Dba Seattle Children's Research Institute 用於实体瘤靶向的双特异性cart细胞
CN109311949B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 储存分离基质的方法
WO2017194593A1 (en) 2016-05-11 2017-11-16 Ge Healthcare Bioprocess R&D Ab Method of cleaning and/or sanitizing a separation matrix
US10513537B2 (en) 2016-05-11 2019-12-24 Ge Healthcare Bioprocess R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
JP7031934B2 (ja) 2016-05-11 2022-03-08 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックス
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
US11339201B2 (en) 2016-05-18 2022-05-24 Albert Einstein College Of Medicine Variant PD-L1 polypeptides, T-cell modulatory multimeric polypeptides, and methods of use thereof
US12448411B2 (en) 2016-09-30 2025-10-21 Cytiva Bioprocess R&D Ab Separation method
EP3532497B1 (en) 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
MX2019007611A (es) 2016-12-22 2020-07-29 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos t y métodos para su uso.
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
CN118453840A (zh) 2017-03-15 2024-08-09 库尔生物制药有限公司 用于调节免疫应答的方法
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP3873930A4 (en) * 2018-10-23 2022-12-07 Magenta Therapeutics, Inc. FC-ALIMINATED ANTIBODY DRUG CONJUGATES (ADCS) AND THEIR USES
CN113412123A (zh) 2018-12-28 2021-09-17 豪夫迈·罗氏有限公司 用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
WO2021027200A1 (en) * 2019-08-13 2021-02-18 Cure Genetics Co., Ltd. Genetically engineered cells and uses thereof
CN110954692A (zh) * 2019-12-20 2020-04-03 蓝怡科技集团股份有限公司 一种还原剂缓冲液及其制备方法和应用
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
CN113880953A (zh) * 2020-07-01 2022-01-04 华夏英泰（北京）生物技术有限公司 T细胞抗原受体、其多聚体复合物及其制备方法和应用
JP2023541366A (ja) 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法
CN112285083B (zh) * 2020-10-28 2022-01-07 上海睿钰生物科技有限公司 一种细胞杀伤效力的评价方法
WO2023097188A1 (en) * 2021-11-24 2023-06-01 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
TW202530261A (zh) * 2023-09-25 2025-08-01 美商奧伊斯特普安生物製藥公司 類胰島素生長因子-1受體(igf1r)抗體及相關治療方法

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2095818B (en) 1981-03-27 1985-10-02 Exxon Research Engineering Co Staged adsorption/resorption heat pump
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5238808A (en) 1984-10-31 1993-08-24 Igen, Inc. Luminescent metal chelate labels and means for detection
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE3825615A1 (de) * 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US5068088A (en) 1988-11-03 1991-11-26 Igen, Inc. Method and apparatus for conducting electrochemiluminescent measurements
ZA898290B (en) 1988-11-03 1991-06-26 Igen Inc Electrochemiluminescent assays
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
IL100866A (en) 1991-02-06 1995-10-31 Igen Inc Method and apparatus for magnetic microparticulate based luminescence assay including plurality of magnets
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
EP1028751B1 (en) 1997-10-31 2008-12-31 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
US7521197B2 (en) * 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
WO1999064597A1 (en) * 1998-06-10 1999-12-16 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services β2 MICROGLOBULIN FUSION PROTEINS AND HIGH AFFINITY VARIANTS
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
KR101077001B1 (ko) 1999-01-15 2011-10-26 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60022369T2 (de) 1999-10-04 2006-05-18 Medicago Inc., Sainte Foy Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
CA2404489A1 (en) * 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
CN102311986B (zh) 2000-10-06 2015-08-19 协和发酵麒麟株式会社 产生抗体组合物的细胞
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
RU2321630C2 (ru) 2001-08-03 2008-04-10 Гликарт Биотекнолоджи АГ Гликозилированные антитела (варианты), обладающие повышенной антителозависимой клеточной цитотоксичностью
US20030157108A1 (en) 2001-10-25 2003-08-21 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
CN102911987B (zh) 2002-04-09 2015-09-30 协和发酵麒麟株式会社 基因组被修饰的细胞
WO2003084569A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Drug containing antibody composition
AU2003236018A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
US20040132140A1 (en) 2002-04-09 2004-07-08 Kyowa Hakko Kogyo Co., Ltd. Production process for antibody composition
JP4628679B2 (ja) 2002-04-09 2011-02-09 協和発酵キリン株式会社 Ｇｄｐ−フコースの輸送に関与する蛋白質の活性が低下または欠失した細胞
US8895020B2 (en) * 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
ES2347241T3 (es) 2002-12-16 2010-10-27 Genentech, Inc. Variantes de inmunoglobulina y sus utilizaciones.
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7378503B2 (en) 2003-04-02 2008-05-27 Hoffmann-La Roche Inc. Antibodies against insulin-like growth factor 1 receptor and uses thereof
US7081432B2 (en) * 2003-07-10 2006-07-25 General Electric Company Alkylation catalyst and method for making alkylated phenols
US20050042218A1 (en) * 2003-07-10 2005-02-24 Vaccinex, Inc. MHC class I - peptide-antibody conjugates with modified beta2-microglobulin
US20080241884A1 (en) 2003-10-08 2008-10-02 Kenya Shitara Fused Protein Composition
US20070134759A1 (en) 2003-10-09 2007-06-14 Harue Nishiya Process for producing antibody composition by using rna inhibiting the function of alpha1,6-fucosyltransferase
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
WO2005053742A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. 抗体組成物を含有する医薬
CN1942483B (zh) 2004-04-13 2012-09-26 弗·哈夫曼-拉罗切有限公司 抗p型选凝素抗体
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
WO2008020827A2 (en) * 2005-08-01 2008-02-21 Biogen Idec Ma Inc. Altered polypeptides, immunoconjugates thereof, and methods related thereto
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
MX2008014722A (es) * 2006-05-19 2011-04-15 Teva Pharma Proteinas de fusion, usos de las mismas y procesos para producir las mismas.
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
CN102369214B (zh) 2009-04-07 2019-04-12 罗氏格黎卡特股份公司 三价、双特异性抗体
EP2435473B1 (en) 2009-05-27 2013-10-02 F.Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins

Similar Documents

Publication Publication Date Title
JP2014519830A5 (enExample)
ES2870991T3 (es) Proteínas inmunomoduladoras con afinidades ajustables
CN106456733B (zh) Syntac多肽及其用途
CN102781960B (zh) Hsa相关组合物及使用方法
JP2013537416A5 (enExample)
JP2020511949A5 (enExample)
WO2019154349A1 (zh) 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2017529059A5 (enExample)
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
US12552867B2 (en) Single chain fusionconstructs comprising multimeric antibody fragments fused to collagen trimerization domains
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
RU2015125639A (ru) Удаление раковых клеток с помощью циркулирующих вирус-специфических цитотоксических т-клеток с использованием направленных против раковых клеток многофункциональных белков, содержащих молекулу гкгс класса i
JP2014124186A (ja) 多価抗体フラグメントおよびその三量体化複合体
US20250243275A1 (en) Multi-domain binding molecules
US11401320B2 (en) QTY FC fusion receptor proteins
KR20230172538A (ko) Fc-유래된 폴리펩티드
JP2023547661A (ja) Ｃｄ３に結合するポリペプチド構築物
CN113874393A (zh) 对hbv包膜蛋白具有特异性的结合分子
JP2025539402A (ja) 遺伝子操作型インターロイキン１０及びその融合タンパク質
US20240408177A1 (en) Interleukin-10 muteins and fusion proteins thereof
WO2020047322A1 (en) Combination therapies comprising tim-3-based chimeric proteins
WO2019106187A1 (en) Antigen-binding molecule format
WO2026016967A1 (zh) 一种融合蛋白及其用途
AU2024372189A1 (en) Multi-chain chimeric polypeptides and uses thereof
WO2023011650A1 (zh) 一种多特异性抗体及其用途